PDF(2946 KB)
Effect of gallic acid in increasing the chemosensitivity of hepatocellular carcinoma HepG2 cells to sorafenib
Baikun LIU, Zhiru WANG, Wenjing ZHAO
PDF(2946 KB)
PDF(2946 KB)
Effect of gallic acid in increasing the chemosensitivity of hepatocellular carcinoma HepG2 cells to sorafenib
Objective To investigate the chemosensitization effect of gallic acid (GA) combined with sorafenib (Sora) on hepatocellular carcinoma HepG2 cells and related mechanisms. Methods HepG2 cells were randomly divided into control group, GA group, Sora group, and GA+Sora group. CCK8 assay was used to measure cell viability; CompuSyn software was used to analyze combination index (CI); colony formation assay was used to evaluate the colony formation ability of cells; flow cytometry was used to measure cell apoptosis; wound healing assay and Transwell chamber assay were used to observe the migration and invasion abilities of cells; Western Blot was used to measure the expression matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9), and apoptosis-related proteins. HepG2 cells were subcutaneously inoculated into the lower right back of mice, and 6 days later, the mice were divided into control group, GA group, Sora group, and GA+Sora group. Tumor size and body weight were measured once a week, and drug intervention was performed for 21 days. Then the nude mice were sacrificed, and tumor weight was measured. A one-way analysis of variance was used for comparison between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results The mean IC50 values of GA and Sora for the treatment of HepG2 cells for 48 hours were 123.47±5.16 μmol/L and 9.87±0.98 μmol/L, respectively, and when Sora was combined with 70 μmol/L GA (IC30), IC50 decreased to 2.06±0.35 μmol/L; the CI value was<1 for Sora at different concentrations combined with 70 μmol/L GA. The number of cell colonies was 234.0±20.4, 147.0±12.1, 129.3±13.3, and 73.0±7.6, respectively, in the four groups, and the GA+Sora group had a significantly lower number of cell colonies than the control group, the GA group, and the Sora group (all P<0.05). After 48 hours of treatment, the cell apoptosis rate was 1.98%±0.29%, 15.17%± 1.56%, 18.65%±1.48%, and 34.60%±5.36%, respectively, in the four groups, and the GA+Sora group had a significantly higher cell apoptosis rate than the control group, the GA group, and the Sora group (all P<0.05). After 24 hours of treatment, the cell migration rate was 55.59%±5.08%, 29.34%±4.36%, 21.80%±5.16%, and 6.47%±2.75%, respectively, in the four groups, and the GA+Sora group had a significantly lower cell migration rate than the control group, the GA group, and the Sora group (all P<0.05). After 48 hours of treatment, the number of transmembrane cells was 223.7±13.0, 168.3±10.9, 155.3±29.1, and 62.7±19.7, respectively, in the four groups, and the GA+Sora group had a significantly lower number of transmembrane cells than the control group, the GA group, and the Sora group (all P<0.05). Compared with the control group, the GA group, the Sora group, and the GA+Sora group had significant reductions in the protein expression levels of MMP-2, MMP-9, and Bcl-2 (all P<0.05) and significant increases in the protein expression levels of Bax and cleaved caspase-3 (all P<0.05). Compared with the control group, the GA, Sora, and GA+Sora groups had significant reductions in tumor volume and weight (all P<0.05), and compared with the Sora group, the GA+Sora group had significant reductions in tumor volume and weight in nude mice (both P<0.05). Conclusion GA can increase the sensitivity of HepG2 cells to Sora chemotherapy, possibly by promoting cell apoptosis and inhibiting cell migration and invasion after combination with Sora.
| 1 |
|
| 2 |
|
| 3 |
杨雪丽, 薛建华, 陈天阳, 等. 苍术酮对肝癌HepG2细胞活性、凋亡的影响及其相关机制[J]. 临床肝胆病杂志, 2021, 37(11): 2589-2594. DOI: 10.3969/j.issn.1001-5256.2021.11.020 .
|
| 4 |
李震, 刘江凯. p53信号通路调控铁死亡在肝细胞癌中的作用机制[J]. 临床肝胆病杂志, 2023, 39(4): 956-960. DOI: 10.3969/j.issn.1001-5256.2023.04.032 .
|
| 5 |
General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009 .
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009 .
|
| 6 |
|
| 7 |
|
| 8 |
艾鑫仪, 侯雪峰, 冯年平. 紫草素与吉非替尼联用逆转人非小细胞肺癌耐药及其机制研究[J]. 中国中药杂志, 2024, 49(1): 175-184. DOI: 10.19540/j.cnki.cjcmm.20230810.401 .
|
| 9 |
|
| 10 |
KO EB,
|
| 11 |
|
| 12 |
|
| 13 |
|
| 14 |
|
| 15 |
|
| 16 |
|
| 17 |
|
| 18 |
陈慧, 宁琳, 蔡丽, 等. 索拉非尼联合吴茱萸碱对肝癌HepG2细胞的协同抗肿瘤作用[J]. 湖北科技学院学报(医学版), 2023, 37(6): 461-464, 480. DOI: 10.16751/j.cnki.2095-4646.2023.06.0461 .
|
| 19 |
陈成, 许汉林, 王平, 等. 猪牙皂皂苷与索拉非尼联用对肝癌HepG2细胞的抑制作用及其机制[J]. 临床和实验医学杂志, 2019, 18(2): 143-146. DOI: 10.3969/j.issn.1671-4695.2019.02.009 .
|
| 20 |
|
| 21 |
王向前, 李清峰, 陈磊, 等. 姜黄素抑制肝细胞癌索拉非尼耐药作用及其调控机制[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(5): 729-735. DOI: 10.3877/cma.j.issn.2095-3232.2024.05.023 .
|
| 22 |
张仲卫, 李志刚, 李彩霞. 没食子酸联合顺铂通过下调环氧化酶-2抑制食管癌的实验研究[J]. 中国中西医结合外科杂志, 2024, 30(4): 562-567. DOI: 10.3969/j.issn.1007-6948.2024.04.025 .
|
| 23 |
|
| 24 |
|
| 25 |
|
| 26 |
韩齐齐, 叶梦然, 金齐力. 去甲泽拉木醛通过抑制AKT/CREB信号通路抑制非小细胞肺癌细胞的增殖、迁移和侵袭[J]. 南方医科大学学报, 2024, 44(2): 280-288. DOI: 10.12122/j.issn.1673-4254.2024.02.10 .
|
| 27 |
许广松, 蒋海兵, 盘箐, 等. 桦木酸对胃癌MGC-803细胞迁移和侵袭的抑制作用及其机制[J]. 吉林大学学报(医学版), 2022, 48(1): 122-128. DOI: 10.13481/j.1671-587X.20220115 .
|
刘百坤负责课题设计,资料分析,撰写论文;王志茹参与收集数据,修改论文;赵文静负责拟定写作思路,指导撰写文章并最后定稿。
/
| 〈 |
|
〉 |